Skip to main content
Top
Published in: Rheumatology International 1/2021

01-01-2021 | Intellectual Disability | Case Based Review

The same mutation in a family with adenosine deaminase 2 deficiency

Authors: Betul Sozeri, Gozde Ercan, Ozlem Akgun Dogan, Jale Yıldız, Ferhat Demir, Levent Doğanay

Published in: Rheumatology International | Issue 1/2021

Login to get access

Abstract

The deficiency of adenosine deaminase 2 (DADA2) has recently been defined as a monogenetic autosomal recessive autoinflammatory disease. DADA2 is mainly characterized by high fever, livedo racemose, early-onset stroke, mild immunodeficiency and clinically polyarteritis nodosa (PAN)-like symptoms. Mutations in CECR1 (cat eye syndrome chromosome region, candidate 1) are responsible for DADA2. Livedoid racemose, lacunar infarct due to involvement in small vessel of the central nervous system, peripheral neuropathy, digital ulcers and loss of fingers are predominantly seen in the disease which could progress to end-stage organ failure and death in some patients. A wide spectrum of severity in phenotype as well as in the age of onset has been reported in the literature. This phenotypic variability is also found in our clinical practice even in patients with the same mutation. Here, we present a family diagnosed with DADA2, with the previously reported p.Gly47Arg mutation in CECR1.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV et al (2014) Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 370(10):911–920CrossRef Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV et al (2014) Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 370(10):911–920CrossRef
2.
go back to reference Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S et al (2014) Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370(10):921–931CrossRef Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S et al (2014) Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370(10):921–931CrossRef
3.
go back to reference Meyts I, Aksentijevich I (2018) Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol 38(5):569–578CrossRef Meyts I, Aksentijevich I (2018) Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol 38(5):569–578CrossRef
4.
go back to reference Hershfield MS (2005) New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 35(1):25–30CrossRef Hershfield MS (2005) New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 35(1):25–30CrossRef
5.
go back to reference Minguet S, Dopfer EP, Pollmer C, Freudenberg MA, Galanos C, Reth M et al (2008) Enhanced B-cell activation mediated by TLR4 and BCR crosstalk. Eur J Immunol 38(9):2475–2487CrossRef Minguet S, Dopfer EP, Pollmer C, Freudenberg MA, Galanos C, Reth M et al (2008) Enhanced B-cell activation mediated by TLR4 and BCR crosstalk. Eur J Immunol 38(9):2475–2487CrossRef
6.
go back to reference Majumdar S, Aggarwal BB (2003) Adenosine suppresses activation of nuclear factor-kappaB selectively induced by tumor necrosis factor in different cell types. Oncogene 22(8):1206–1218CrossRef Majumdar S, Aggarwal BB (2003) Adenosine suppresses activation of nuclear factor-kappaB selectively induced by tumor necrosis factor in different cell types. Oncogene 22(8):1206–1218CrossRef
7.
go back to reference Simmonds HA, Webster DR, Perrett D, Reiter S, Levinsky RJ (1982) Formation and degradation of deoxyadenosine nucleotides in inherited adenosine deaminase deficiency. Biosci Rep 2(5):303–314CrossRef Simmonds HA, Webster DR, Perrett D, Reiter S, Levinsky RJ (1982) Formation and degradation of deoxyadenosine nucleotides in inherited adenosine deaminase deficiency. Biosci Rep 2(5):303–314CrossRef
8.
go back to reference Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G (2010) Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol 88(2):279–290CrossRef Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G (2010) Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol 88(2):279–290CrossRef
9.
go back to reference Iwaki-Egawa S, Yamamoto T, Watanabe Y (2006) Human plasma adenosine deaminase 2 is secreted by activated monocytes. Biol Chem 387(3):319–321CrossRef Iwaki-Egawa S, Yamamoto T, Watanabe Y (2006) Human plasma adenosine deaminase 2 is secreted by activated monocytes. Biol Chem 387(3):319–321CrossRef
10.
go back to reference Schrader WP, Pollara B, Meuwissen HJ (1978) Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency. Proc Natl Acad Sci USA 75(1):446–450CrossRef Schrader WP, Pollara B, Meuwissen HJ (1978) Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency. Proc Natl Acad Sci USA 75(1):446–450CrossRef
11.
go back to reference Van Eyck L, Jr Hershfield MS, Pombal D, Kelly SJ, Ganson NJ, Moens L et al (2015) Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol 135(1):283–287CrossRef Van Eyck L, Jr Hershfield MS, Pombal D, Kelly SJ, Ganson NJ, Moens L et al (2015) Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol 135(1):283–287CrossRef
12.
go back to reference Bae MJ, Ryu S, Kim HJ, Cha SI, Kim CH, Lee J (2017) Mycobacterium tuberculosis ESAT6 and CPF10 induce adenosine deaminase 2 mRNA expression in monocyte-derived macrophages. Tuberc Respir Dis (Seoul) 80(1):77–82CrossRef Bae MJ, Ryu S, Kim HJ, Cha SI, Kim CH, Lee J (2017) Mycobacterium tuberculosis ESAT6 and CPF10 induce adenosine deaminase 2 mRNA expression in monocyte-derived macrophages. Tuberc Respir Dis (Seoul) 80(1):77–82CrossRef
13.
go back to reference Valdes L, San Jose E, Alvarez D, Valle JM (1996) Adenosine deaminase (ADA) isoenzyme analysis in pleural effusions: diagnostic role, and relevance to the origin of increased ADA in tuberculous pleurisy. Eur Respir J 9(4):747–751CrossRef Valdes L, San Jose E, Alvarez D, Valle JM (1996) Adenosine deaminase (ADA) isoenzyme analysis in pleural effusions: diagnostic role, and relevance to the origin of increased ADA in tuberculous pleurisy. Eur Respir J 9(4):747–751CrossRef
14.
go back to reference Sari RA, Taysi S, Yilmaz O, Bakan N (2003) Correlation of serum levels of adenosine deaminase activity and its isoenzymes with disease activity in rheumatoid arthritis. Clin Exp Rheumatol 21(1):87–90PubMed Sari RA, Taysi S, Yilmaz O, Bakan N (2003) Correlation of serum levels of adenosine deaminase activity and its isoenzymes with disease activity in rheumatoid arthritis. Clin Exp Rheumatol 21(1):87–90PubMed
15.
go back to reference Fernandez E, Rodrigo L, Riestra S, Carcia S, Gutierrez F, Ocio G (2000) Adenosine deaminase isoenzymes and neopterin in liver cirrhosis. J Clin Gastroenterol 30(2):181–186CrossRef Fernandez E, Rodrigo L, Riestra S, Carcia S, Gutierrez F, Ocio G (2000) Adenosine deaminase isoenzymes and neopterin in liver cirrhosis. J Clin Gastroenterol 30(2):181–186CrossRef
16.
go back to reference Gasparyan AY, Ayvazyan L, Blackmore H (2011) Kitas GD Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417CrossRef Gasparyan AY, Ayvazyan L, Blackmore H (2011) Kitas GD Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417CrossRef
17.
go back to reference Ozen S, Bilginer Y, Batu ED, Taşkıran E, Özkara HA, Ünal Ş, Güleray N, Erden A, Karadağ Ö, Gümrük F, Çetin M, Sönmez HE, Ayvaz DÇ, Tezcan I (2019) A monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase 2 Subtitle: Deficiency of adenosine deaminase. J Rheumatol. https://doi.org/10.3899/jrheum.181384CrossRefPubMed Ozen S, Bilginer Y, Batu ED, Taşkıran E, Özkara HA, Ünal Ş, Güleray N, Erden A, Karadağ Ö, Gümrük F, Çetin M, Sönmez HE, Ayvaz DÇ, Tezcan I (2019) A monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase 2 Subtitle: Deficiency of adenosine deaminase. J Rheumatol. https://​doi.​org/​10.​3899/​jrheum.​181384CrossRefPubMed
18.
go back to reference Garg N, Kasapcopur O, Foster J 2nd, Barut K, Tekin A, Kizilkilic O et al (2014) Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy. Eur J Pediatr 173(6):827–830CrossRef Garg N, Kasapcopur O, Foster J 2nd, Barut K, Tekin A, Kizilkilic O et al (2014) Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy. Eur J Pediatr 173(6):827–830CrossRef
19.
go back to reference Batu ED, Karadag O, Taskiran EZ, Kalyoncu U, Aksentijevich I, Alikasifoglu M et al (2015) A case series of adenosine deaminase 2- deficient patients emphasizing treatment and genotype-phenotype correlations. J Rheumatol 42(8):1532–1534CrossRef Batu ED, Karadag O, Taskiran EZ, Kalyoncu U, Aksentijevich I, Alikasifoglu M et al (2015) A case series of adenosine deaminase 2- deficient patients emphasizing treatment and genotype-phenotype correlations. J Rheumatol 42(8):1532–1534CrossRef
20.
go back to reference Trotta L, Martelius T, Siitonen T, Hautala T, Hamalainen S, Juntti H et al (2018) ADA2 deficiency: clonal lymphoproliferation in a subset of patients. J Allergy Clin Immunol 141(1534–1537):e8 Trotta L, Martelius T, Siitonen T, Hautala T, Hamalainen S, Juntti H et al (2018) ADA2 deficiency: clonal lymphoproliferation in a subset of patients. J Allergy Clin Immunol 141(1534–1537):e8
21.
go back to reference Sundin M, Marits P, Nierkens S, Kolios AGA, Nilsson J (2019) "Immune" thrombocytopenia as key feature of a novel ADA2 deficiency variant: implication on differential diagnostics of ITP in children. J Pediatr Hematol Oncol 41(2):155–157CrossRef Sundin M, Marits P, Nierkens S, Kolios AGA, Nilsson J (2019) "Immune" thrombocytopenia as key feature of a novel ADA2 deficiency variant: implication on differential diagnostics of ITP in children. J Pediatr Hematol Oncol 41(2):155–157CrossRef
22.
go back to reference Van Eyck L, Liston A, Wouters C (2014) Mutant ADA2 in vasculopathies. N Engl J Med 371(5):480PubMed Van Eyck L, Liston A, Wouters C (2014) Mutant ADA2 in vasculopathies. N Engl J Med 371(5):480PubMed
23.
go back to reference Nanthapisal S, Murphy C, Omoyinmi E, Hong Y, Standing A, Berg S et al (2016) Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol 68(9):2314–2322CrossRef Nanthapisal S, Murphy C, Omoyinmi E, Hong Y, Standing A, Berg S et al (2016) Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol 68(9):2314–2322CrossRef
24.
go back to reference Ombrello ASD, Hoffmann P, Jones A, Barham B, Barron K, Flegel W et al (2015) The deficiency of adenosine deaminase type 2-results of therapeutic intervention. Pediatr Rheumatol 13(1):O40CrossRef Ombrello ASD, Hoffmann P, Jones A, Barham B, Barron K, Flegel W et al (2015) The deficiency of adenosine deaminase type 2-results of therapeutic intervention. Pediatr Rheumatol 13(1):O40CrossRef
25.
go back to reference Bucciol G, Delafontaine S, Segers H, Bossuyt X, Hershfield MS, Moens L et al (2017) Hematopoietic stem cell transplantation in ADA2 deficiency: early restoration of ADA2 enzyme activity and disease relapse upon drop of donor chimerism. J Clin Immunol 37(8):746–750CrossRef Bucciol G, Delafontaine S, Segers H, Bossuyt X, Hershfield MS, Moens L et al (2017) Hematopoietic stem cell transplantation in ADA2 deficiency: early restoration of ADA2 enzyme activity and disease relapse upon drop of donor chimerism. J Clin Immunol 37(8):746–750CrossRef
26.
go back to reference Van Montfrans JM, Hartman EA, Braun KP, Hennekam EA, Hak EA, Nederkoorn PJ et al (2016) Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford) 55(5):902–910CrossRef Van Montfrans JM, Hartman EA, Braun KP, Hennekam EA, Hak EA, Nederkoorn PJ et al (2016) Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford) 55(5):902–910CrossRef
27.
go back to reference Caorsi R, Penco F, Grossi A, Insalaco A, Omenetti A, Alessio M et al (2017) ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis 76(10):1648–1656CrossRef Caorsi R, Penco F, Grossi A, Insalaco A, Omenetti A, Alessio M et al (2017) ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis 76(10):1648–1656CrossRef
Metadata
Title
The same mutation in a family with adenosine deaminase 2 deficiency
Authors
Betul Sozeri
Gozde Ercan
Ozlem Akgun Dogan
Jale Yıldız
Ferhat Demir
Levent Doğanay
Publication date
01-01-2021
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 1/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04444-z

Other articles of this Issue 1/2021

Rheumatology International 1/2021 Go to the issue